MoonLake is a cash-burning pre-profitability biotech trading 25% below the analyst consensus price target, with quality metrics below the minimum investable floor and a persistent earnings miss pattern — the primary signal is a structural quality disqualification that argues for exiting existing positions rather than adding.
Thesis pillars
- Quality Below Minimum Floor↓Deteriorating
- Bearish Options Positioning High Iv↓Deteriorating
- Persistent Earnings Miss Pattern↑Improving
- +1 more pillar — see the Why tab for full reasoning
MoonLake Immunotherapeutics (MLTX) Stock Analysis
Inst Constrain edge
Healthcare · Biotechnology
Sell if holding. Engine safety override at $16.50: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.9/10 and A.R:R 4.5:1 is above the 1.5:1 BUY gate. Specifically: Elevated put/call ratio: 1.32; Below-average business quality; Negative price momentum. (Note: Risk dimension 4.6/10 and A.R:R 4.5:1 are different metrics that happen to read the same number here.)
MoonLake Immunotherapeutics is a clinical-stage biotechnology company developing SLK, a single tri-specific Nanobody licensed from Merck Healthcare KGaA (MHKDG), to treat IL-17A/F-driven inflammatory diseases including hidradenitis suppurativa, psoriatic arthritis, axial... Read more
Sell if holding. Engine safety override at $16.50: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.9/10 and A.R:R 4.5:1 is above the 1.5:1 BUY gate. Specifically: Elevated put/call ratio: 1.32; Below-average business quality; Negative price momentum. (Note: Risk dimension 4.6/10 and A.R:R 4.5:1 are different metrics that happen to read the same number here.) Chart setup: No clear chart pattern; technical signals are mixed. Score 4.9/10, moderate confidence.
Passes 6/8 gates (favorable risk/reward ratio, no SEC red flags, news boost analyst 0.80, earnings proximity 81d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and clean insider activity. Suitability: speculative.
Recent developments
updated 2026-08-15Recent Developments — MoonLake Immunotherapeutics
Latest news
- NEWS HC Wainwright & Co. Maintains Buy on MoonLake, Raises Price Target to $50 — benzinga Aug 13, 2026 positive
- NEWS MoonLake Immunotherapeutics Filed For Mixed Shelf Offering, Size Not Disclosed — benzinga Aug 10, 2026 neutral
- NEWS MoonLake’s Psoriatic Arthritis Drug Shows Promise In Late-Stage Study — benzinga Aug 10, 2026 positive
- NEWS MoonLake Immunotherapeutics Reports Topline Results From Phase 3 IZAR-1 Trial Showing Sonelokimab Met All Week 16 Endpoi — benzinga Aug 10, 2026 positive
- NEWS MoonLake Q2 EPS $(0.84) Beats $(0.93) Estimate — benzinga Aug 10, 2026 positive
Generated 2026-08-15T13:12:18Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHpipelineSLK10-K Item 1: 'We are currently a single asset company focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody, that we exclusively licensed from MHKDG'
- HIGHcounterpartyMHKDG license10-K Item 1A: 'Our business relies on certain licensing rights from MHKDG and RCT that can be terminated in certain circumstances.'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers·1 ceiling hit
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $16.50: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.9/10 and A.R:R 4.5:1 is above the 1.5:1 BUY gate. Specifically: Elevated put/call ratio: 1.32; Below-average business quality; Negative price momentum. (Note: Risk dimension 4.6/10 and A.R:R 4.5:1 are different metrics that happen to read the same number here.) Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $15.45. Score 4.9/10, moderate confidence.
Take-profit target: $24.83 (+50.7% upside). Prior stop was $15.45. Stop-loss: $15.45.
Concentration risk — Pipeline: SLK; Concentration risk — Counterparty: MHKDG license; Quality below floor (1.6 < 4.0).
MoonLake Immunotherapeutics trades at a P/E of N/A (forward -4.9). TrendMatrix value score: 9.0/10. Verdict: Sell.
22 analysts cover MLTX with a consensus score of 4.0/5. Average price target: $29.
What does MoonLake Immunotherapeutics do?MoonLake Immunotherapeutics is a clinical-stage biotechnology company developing SLK, a single tri-specific Nanobody...
MoonLake Immunotherapeutics is a clinical-stage biotechnology company developing SLK, a single tri-specific Nanobody licensed from Merck Healthcare KGaA (MHKDG), to treat IL-17A/F-driven inflammatory diseases including hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and palmoplantar pustulosis. The company has no products approved for commercial sale and reported a net loss of $230.3 million in 2025, with a planned BLA submission for SLK in HS expected in the second half of 2026 and a potential U.S. commercial launch in the second half of 2027.